---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001545"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:32:37.670971+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica sees Q4 rev $6.0-6.2M (+46-51% YoY); FY rev up ~360%

## Summary
- Q4 2022 revenue expected $6.0-$6.2M, +46-51% vs Q4 2021, driven by PulseVet and Assisi.
- Full-year 2022 revenue expected $18.6-$18.9M, +354-361% over 2021.
- Gross margin for FY 2022 expected ~72%.
- Cash, cash equivalents and available-for-sale securities ~$156M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001654954-23-001545
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495423001545/0001654954-23-001545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495423001545/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001545
- JSON: https://secwatch.observer/filing/0001654954-23-001545.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001545.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported fourth quarter and year ended 2022 results: revenue approximately $6.0-$6.2 million.
  - Period: fourth quarter and year ended 2022
  - Revenue: approximately $6.0-$6.2 million
  - Result: preliminary results
  source text: Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495423001545/0001654954-23-001545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.